Dartmouth-Hitchcock Medical Center and Dartmouth Medical School, Section of Surgical Oncology, Lebanon, NH, USA.
Cancer Chemother Pharmacol. 2011 Jan;67 Suppl 1:S3-8. doi: 10.1007/s00280-010-1516-5. Epub 2010 Nov 30.
Adjuvant therapy for primary GIST has proven benefit in extending disease free survival. Defined risk factors for recurrent disease are based on GIST size, location, and mitotic rate and provide useful guidelines for selecting patients for adjuvant therapy considerations. Neoadjuvant therapy with tyrosine kinase inhibition has potential usefulness in primary GIST, although not yet as standard of care. Advantages can include tumor downsizing to provide opportunity for less morbid surgical resection as well as to decrease risk of intra-op tumor rupture. These theoretical considerations have not been evaluated in large clinical studies.
辅助治疗原发性 GIST 已被证明可延长无疾病生存时间。复发疾病的明确危险因素基于 GIST 大小、位置和有丝分裂率，并为选择接受辅助治疗的患者提供了有用的指导。酪氨酸激酶抑制的新辅助治疗对原发性 GIST 具有潜在的作用，尽管尚未成为标准治疗。其优点包括肿瘤缩小，为减少手术切除带来的高风险提供了机会，还可以降低术中肿瘤破裂的风险。这些理论考虑尚未在大型临床研究中得到评估。
